Skip to main content
EMR
NYSE Manufacturing

Emerson Tops Q4 Estimates, Lifts Dividend 7%, Sets FY27 Adjusted EPS Guidance Near $7.25

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Industrial Machinery Stocks · Industrial
Sentiment info
Positive
Importance info
7
Price
$166.4
Mkt Cap
$92.812B
52W Low
$122.635
52W High
$171.25
52W Position info
36% above low
Off High info
2.8% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

EMR sits 36% above its 52-week low of $122.635.

Summary

Emerson posted Q4 adjusted EPS of $1.86, up 15%, on 7% sales growth, raised its quarterly dividend 7% to $0.595, and guided FY27 adjusted EPS to about $7.25 with $3.8-3.9 billion of free cash flow.


Key Events · Earnings and Guidance · EMR

  • Q4 Sales and EPS Beat

    Q4 net sales came in at $5,201 million, up 7% from $4,855 million, while adjusted EPS of $1.86 rose 15% from $1.62; GAAP EPS was $1.33, up 24%.

  • Orders and Margins Expand

    Underlying orders grew 14% in Q4 and 9% for the full year. Q4 pretax margin reached 19.2% versus 15.6% a year earlier, and adjusted segment EBITA margin rose 160 bps to 29.1%.

  • Dividend Raised 7%

    The quarterly dividend rises to $0.595 per share, payable December 10, 2026 to stockholders of record November 13, 2026.

  • Initial FY27 Guidance

    Management guides FY27 net sales growth of ~5%, adjusted EPS of ~$7.25, operating cash flow of $4.3-4.4 billion and free cash flow of $3.8-3.9 billion.


Analysis · EMR · Manufacturing

Emerson closed fiscal 2026 ahead of expectations, with Q4 sales up 7% to $5.2 billion and adjusted EPS up 15% to $1.86 as underlying orders rose 14% on long-cycle project activity. The board lifted the quarterly dividend 7% to $0.595, and management issued initial FY27 guidance of roughly $7.25 in adjusted EPS alongside $3.8-3.9 billion of free cash flow, enough to fund about $3.8 billion in buybacks and dividends. With the stock near its 52-week high, the bar was already elevated; the guidance framework, rather than the backward-looking quarter, is what sets the next leg of the thesis.

How filings like this one have moved

In the 30 days to Nov 4, 2026, 32.4% of the 2240 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, EMR was trading at $166.40 on NYSE in the Manufacturing sector, with a market capitalization of approximately $92.8B. The 52-week trading range was $122.64 to $171.25. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

EMR - Latest Insights

EMR
Sep 15, 2026, 10:36 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $146.88
Real-time Price: $162.81 info
Change: +$15.93 (+11%) info
Market Cap: $92.812B info
EMR
Aug 06, 2026, 9:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $156.50
Real-time Price: $162.81 info
Change: +$6.31 (+4%) info
Market Cap: $92.812B info
EMR
Aug 04, 2026, 5:47 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $153.00
Real-time Price: $162.81 info
Change: +$9.81 (+6%) info
Market Cap: $92.812B info
EMR
Aug 04, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $155.00
Real-time Price: $162.81 info
Change: +$7.81 (+5%) info
Market Cap: $92.812B info
EMR
Aug 04, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $155.00
Real-time Price: $162.81 info
Change: +$7.81 (+5%) info
Market Cap: $92.812B info